Dosage forms and related therapies

a technology of doses and therapeutic agents, applied in the direction of drug compositions, antinoxious agents, metabolic disorders, etc., can solve the problems of 40% of deaths in patients who have not experienced the reduction of increase in age-adjusted heart disease mortality, etc., to improve the structural and functional repair of damaged tissues, impaired tissue behavior, and impaired wound repair

a technology of doses and therapeutic agents, applied in the direction of drug compositions, antinoxious agents, metabolic disorders, etc., can solve the problems of 40% of deaths in patients who have not experienced the reduction of increase in age-adjusted heart disease mortality, etc., to improve the structural and functional repair of damaged tissues, impaired tissue behavior, and impaired wound repair

US20060100278A1Inactive Publication Date: 2006-05-11PHILERA NEW ZEALAND

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Dosage forms and related therapies
  • Dosage forms and related therapies
  • Dosage forms and related therapies

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0260] This Example was carried out to determine for the sake of subsequent comparison baseline physiological data relating to the effects of streptozotocin (STZ) treatment in rats, in addition to baseline physiological data from diabetic and nondiabetic rats.

[0261] All methods used in this study were approved by the University of Auckland Animal Ethics Committee and were in accordance with The Animals Protection Act and Regulations of New Zealand.

[0262] In order to induce diabetes, male Wistar rats (n=28, 303±2.9 g) were divided randomly into diabetic and nondiabetic groups. Following induction of anesthesia (5% halothane and 21.min−1 O2), animals in the diabetic group received a single intravenous dose of streptozotocin (STZ, 55 mg.kg−1 body weight, Sigma; St. Louis, Mo.) in 0.5 ml saline administered via the tail vein. Nondiabetic animals received an equivalent volume of saline. Following injection, both diabetic and nondiabetic rats were housed in like-pairs and provided with ...

example 2

[0265] This Example assessed the effect of acute intravenous administration of increasing doses of trientine on the excretion profiles of copper and iron in the urine of diabetic and nondiabetic rats.

[0266] Six to seven weeks (mean=44±1 days) after administration of STZ, animals underwent either a control or drug experimental protocol. All animals were fasted overnight prior to surgery but continued to have ad libitum access to deionized water. Induction and maintenance of surgical anesthesia was by 3-5% halothane and 21.min−1 O2. The femoral artery and vein were cannulated with a solid-state blood pressure transducer (Mikrotip™ 1.4F, Millar Instruments, Texas, USA) and a saline filled PE 50 catheter respectively. The ureters were exposed via a midline abdominal incision, cannulated using polyethylene catheters (external diameter 0.9 mm, internal diameter 0.5 mm) and the wound sutured closed. The trachea was cannulated and the animal ventilated at 70-80 breaths.min−1 with air suppl...

example 3

[0281] This example was carried out to determine the effect of acute intravenous administration of increasing doses of trientine on the copper and iron content of cardiac tissue in normal and diabetic rates.

[0282] Methods were carried out as follows. Spectrophotometric analysis was conducted as described in Example 2. Cu, Fe and Zn in tissue digests were determined at Hill Laboratories (Hamilton, New Zealand) using either a PE Sciex Elan-6000 or PE Sciex Elan-6100 DRC ICP-MS. The operating parameters are summarized in the Table below.

Instrumental operating parameters for ICP-MSParameterValueInductively coupled plasmaRadiofrequency power1500 WArgon plasma gas flow rate15 l · min−1Argon auxiliary gas flow rate1.2 l · min−1Argon nebuliser gas flow rate0.89 l · min−1InterfaceSampler cone and orifice diameterNi / 1.1 mmSkimmer cone and orifice diameterNi / 0.9 mmData acquisition parametersScanning modePeak hoppingDwell time30 ms (Cu, Zn) / 100 ms (Fe)Sweeps / replicate20Replicates 3Sample upt...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Massaaaaaaaaaa
Massaaaaaaaaaa
Massaaaaaaaaaa
Login to View More

Abstract

This invention is directed in part to novel doses, dosage formulations, and routes of administration of such doses and dose formulations, said dose and dose formulations containing one or more copper chelators, for example, one or more trientine active agents, including trientine analogues, trientine salts, trientine prodrugs, and trientine derivatives, useful in the treatment of diseases, disorders and conditions, including in indications where copper may play a role.

Description

FIELD OF THE INVENTION [0001] The subject invention pertains to doses and dosage forms of therapeutic agents and their use in methods for the treatment, reversal or amelioration of diseases, disorders and / or conditions in a mammal (hereafter “treating”). Mammals that may be treated using the described and claimed doses and dosage forms include, for example, a human being having, or at risk for developing, microvascular and / or macrovascular damage, for example, cardiovascular tissue damage and, in particular, mammals including human beings that have or are at risk for developing undesired copper levels, including copper levels that can cause or lead to tissue damage, including but not limited to vessel damage. Treatment includes but is not limited to therapies to ameliorate and / or reverse, in whole or in part, damage resulting from diseases, disorders or conditions that are characterized in any part by copper-involved or mediated damage of tissue and / or vasculature, and / or to copper-...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
11 May 2006
Publication
US20060100278A1
IPC
A61K31/205; A61K31/30; A61P3/10; A61P9/00
CPC
A61K31/30; A61K31/131; A61K31/194; A61K31/132; A61P39/04; A61P43/00; A61P9/00; A61P9/04
Inventors
COOPER, GARTH JAMES SMITH; BAKER, JOHN RICHARD